BR112021022311A2 - Polipeptídeo ix adenoviral aumenta produtividade e infectividade de vetor adenoviral de terapia gênica - Google Patents

Polipeptídeo ix adenoviral aumenta produtividade e infectividade de vetor adenoviral de terapia gênica

Info

Publication number
BR112021022311A2
BR112021022311A2 BR112021022311A BR112021022311A BR112021022311A2 BR 112021022311 A2 BR112021022311 A2 BR 112021022311A2 BR 112021022311 A BR112021022311 A BR 112021022311A BR 112021022311 A BR112021022311 A BR 112021022311A BR 112021022311 A2 BR112021022311 A2 BR 112021022311A2
Authority
BR
Brazil
Prior art keywords
adenoviral
vector
polypeptide
gene therapy
infectivity
Prior art date
Application number
BR112021022311A
Other languages
English (en)
Inventor
Hanna Lesch
Saana Lepola
Seppo Yla-Herttuala
Vesa Turkki
Original Assignee
Kuopio Center for Gene and Cell Therapy Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kuopio Center for Gene and Cell Therapy Oy filed Critical Kuopio Center for Gene and Cell Therapy Oy
Publication of BR112021022311A2 publication Critical patent/BR112021022311A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C12N7/025—Packaging cell lines, e.g. transcomplementing cell lines, for production of virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/00051—Methods of production or purification of viral material
    • C12N2710/00052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Manufacturing & Machinery (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

polipeptídeo ix adenoviral aumenta produtividade e infectividade de vetor adenoviral de terapia gênica. a produção do vetor adenoviral de terapia gênica em células produtoras que expressam ou superexpressam o polipeptídeo ix adenoviral ou formas truncadas do mesmo permite que se produza adenovírus com pix deletado em cultura celular de suspensão. o uso de células produtoras que expressam ou superexpressam polipeptídeo ix adenoviral ou formas truncadas do mesmo também aumenta o rendimento de vetor de adenovírus, independentemente se aquele adenovírus tiver deleção de pix. o uso de células produtoras que expressam ou superexpressam o polipeptídeo ix adenoviral ou formas truncadas do mesmo também melhora a cinética de transdução do vetor resultante, reduzindo o número de pfu/célula-alvo requerido para alcançar um determinado nível de transdução/infecção, encurtando o tempo que o vetor requer para transduzir ou infectar uma célula-alvo, e encurtando o tempo que uma célula-alvo infectada produz vírus de progênie.
BR112021022311A 2019-05-07 2020-05-01 Polipeptídeo ix adenoviral aumenta produtividade e infectividade de vetor adenoviral de terapia gênica BR112021022311A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962844175P 2019-05-07 2019-05-07
US16/423,215 US20190315808A1 (en) 2019-05-07 2019-05-28 Adenoviral Polypeptide IX Increases Adenoviral Gene Therapy Vector Productivity and Infectivity
US16/569,742 US20200354409A1 (en) 2019-05-07 2019-09-13 Adenoviral Polypeptide IX Increases Adenoviral Gene Therapy Vector Productivity and Infectivity
PCT/US2020/030924 WO2020227049A1 (en) 2019-05-07 2020-05-01 Adenoviral polypeptide ix increases adenoviral gene therapy vector productivity and infectivity

Publications (1)

Publication Number Publication Date
BR112021022311A2 true BR112021022311A2 (pt) 2021-12-28

Family

ID=68160233

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021022311A BR112021022311A2 (pt) 2019-05-07 2020-05-01 Polipeptídeo ix adenoviral aumenta produtividade e infectividade de vetor adenoviral de terapia gênica

Country Status (11)

Country Link
US (2) US20190315808A1 (pt)
EP (1) EP3965787A4 (pt)
JP (1) JP2022532138A (pt)
KR (1) KR20220012863A (pt)
CN (1) CN114450017A (pt)
AU (1) AU2020267343A1 (pt)
BR (1) BR112021022311A2 (pt)
CA (1) CA3136313A1 (pt)
IL (1) IL287846A (pt)
MX (1) MX2021013597A (pt)
WO (1) WO2020227049A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190315808A1 (en) * 2019-05-07 2019-10-17 Kuopio Center for Gene and Cell Therapy Oy Adenoviral Polypeptide IX Increases Adenoviral Gene Therapy Vector Productivity and Infectivity

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880102A (en) * 1995-01-17 1999-03-09 Duke University Adenoviral vector system
WO1999057296A1 (en) * 1998-05-01 1999-11-11 Genzyme Corporation Partially deleted adenoviral vectors
AU2001291162A1 (en) * 2000-09-25 2002-04-08 Regents Of The University Of Michigan Production of viral vectors
JP2005536231A (ja) * 2002-05-08 2005-12-02 イントロン，インコーポレーテッド アデノウイルスに細胞選択的複製をもたらすための、スプライセオソーム媒介型ｒｎａトランススプライシングの使用
US20090253184A1 (en) * 2008-01-23 2009-10-08 Introgen Therapeutics, Inc. Compositions and methods related to an adenoviral trans-complementing cell line
CA2792537A1 (en) * 2010-03-30 2011-10-06 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
US20190315808A1 (en) * 2019-05-07 2019-10-17 Kuopio Center for Gene and Cell Therapy Oy Adenoviral Polypeptide IX Increases Adenoviral Gene Therapy Vector Productivity and Infectivity

Also Published As

Publication number Publication date
CA3136313A1 (en) 2020-11-12
CN114450017A (zh) 2022-05-06
US20190315808A1 (en) 2019-10-17
US20200354409A1 (en) 2020-11-12
KR20220012863A (ko) 2022-02-04
EP3965787A4 (en) 2023-09-13
JP2022532138A (ja) 2022-07-13
EP3965787A1 (en) 2022-03-16
AU2020267343A1 (en) 2021-12-16
IL287846A (en) 2022-01-01
WO2020227049A1 (en) 2020-11-12
MX2021013597A (es) 2022-02-11

Similar Documents

Publication Publication Date Title
Cheng et al. Merkel cell polyomavirus large T antigen has growth-promoting and inhibitory activities
SA520412637B1 (ar) B7 الفيروس الغدي الحال للورم المشفِّر لبروتين
BR112022009895A2 (pt) Construtos de terapia de gene de microdistrofina e usos dos mesmos
CL2017002199A1 (es) Vectores retrovirales a lentivirales
MX2019001186A (es) Metodos para evaluar la presencia o la ausencia de un virus capaz de replicacion.
WO2020097372A8 (en) Use of adeno-associated viral vectors to correct gene defects/ express proteins in hair cells and supporting cells in the inner ear
Meng et al. C7L family of poxvirus host range genes inhibits antiviral activities induced by type I interferons and interferon regulatory factor 1
Sturgill et al. Natural killer cell evasion is essential for infection by rhesus cytomegalovirus
BR112021024127A2 (pt) Adenovírus modificado
EA201791630A1 (ru) Аналитическое ультрацентрифугирование для определения характеристик рекомбинантных вирусных частиц
Kraus et al. Vaccination directed against the human endogenous retrovirus-K (HERV-K) gag protein slows HERV-K gag expressing cell growth in a murine model system
Olson et al. Deletion of the vaccinia virus B1 kinase reveals essential functions of this enzyme complemented partly by the homologous cellular kinase VRK2
PH12020550117A1 (en) Variant rnai
BR112021022311A2 (pt) Polipeptídeo ix adenoviral aumenta produtividade e infectividade de vetor adenoviral de terapia gênica
Ran et al. White spot syndrome virus IE1 and WSV056 modulate the G1/S transition by binding to the host retinoblastoma protein
Habison et al. Cross-species conservation of episome maintenance provides a basis for in vivo investigation of Kaposi's sarcoma herpesvirus LANA
Xuan et al. ZAP inhibits murine gammaherpesvirus 68 ORF64 expression and is antagonized by RTA
Ali et al. APOBEC3 inhibits DEAD-END function to regulate microRNA activity
Rahm et al. Unique spectrum of activity of prosimian TRIM5α against exogenous and endogenous retroviruses
CL2021002226A1 (es) Transactivadores de dominios de unión a adn y usos de estos
Chang et al. Increased ATP generation in the host cell is required for efficient vaccinia virus production
BR112022005963A2 (pt) Células com expressão de transgenes sustentada
Mai et al. PML alternative splice products differentially regulate HAdV productive infection
Yang et al. Downregulation of Mdm2 and Mdm4 enhances viral gene expression during adenovirus infection
Kutle et al. Murine cytomegalovirus M25 proteins sequester the tumor suppressor protein p53 in nuclear accumulations

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]